Sulfasalazine

N-acetyltransferase 2 ; Homo sapiens







15 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33094670 Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review. 2021 Jan 1
2 32107440 The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. 2020 Feb 27 5
3 24394199 Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. 2014 Aug 1
4 20040334 Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. 2010 Jan 3
5 18167504 Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. 2008 Jul 1
6 18398952 Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis. 2008 Apr 1
7 18680473 Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. 2008 Jul 1
8 17377643 N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. 2007 Mar 3
9 17502830 Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. 2007 Jun 2
10 15032315 N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. 2004 Feb 1
11 12186410 N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. 2002 Aug 2
12 12465141 Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. 2002 Dec 5
13 11642327 N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. 2001 Oct 2
14 10739170 Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. 2000 Feb 3
15 9170150 NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. 1997 Apr 1